Drug Profile
Research programme: cancer and infectious disease monoclonal antibodies - Morphotek/Alexion AstraZeneca Rare Disease
Latest Information Update: 29 Jul 2021
Price :
$50
*
At a glance
- Originator Morphotek; Synageva BioPharma
- Developer Alexion AstraZeneca Rare Disease
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Infections
Most Recent Events
- 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Infections in USA (Parenteral)